Oncolytic Virus Alphavirus M1: A New and Promising Weapon to Fight Cancer

Ferlay J , Colombet M , Soerjomataram I , et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer, 2019; 144:1941–1953.

Hemminki O , Oksanen M , Taipale K , et al. Oncograms visualize factors influencing long-term survival of cancer patients treated with adenoviral oncolytic immunotherapy. Mol Ther Oncolytics, 2018; 9:41–50.

Zhang L , Hemminki O , Chen T , et al. Second cancers and causes of death in patients with testicular cancer in Sweden. PLoS One, 2019; 14:e0214410.

Kazandjian D , Suzman DL , Blumenthal G , et al. FDA approval summary: Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist, 2016; 21:634–642.

Boyiadzis MM , Kirkwood JM , Marshall JL , et al. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer, 2018; 6:35.

Bouziana S , Bouzianas D . Anti-CD19 CAR-T cells: digging in the dark side of the golden therapy. Crit Rev Oncol Hematol, 2021; 157:103096.

Uchida H , Marzulli M , Nakano K , et al. Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol Ther, 2013; 21:561–569.

Kaufman HL , Kohlhapp FJ , Zloza A . Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov, 2015; 14:642–662.

Alcami A. Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol, 2003; 3:36–50.

Andtbacka RH , Kaufman HL , Collichio F , et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol, 2015; 33:2780–2788.

Dan J , Nie L , Jia X , et al. Visualization of the oncolytic alphavirus M1 life cycle in cancer cells. Virol Sin 2021. https://doi.org/10.1007/s12250-020-00339-7

Cai J , Yan G. The identification and development of a novel oncolytic virus: alphavirus M1. Hum Gene Ther 2021.

Li XD , Qiu FX , Yang H , et al. Isolation of Getah virus from mosquitos collected on Hainan Island, China, and results of a serosurvey. Southeast Asian J Trop Med Public Health, 1992; 23:730–734.

Hu J , Cai XF , Yan G . Alphavirus M1 induces apoptosis of malignant glioma cells via downregulation and nucleolar translocation of p21WAF1/CIP1 protein. Cell Cycle, 2009; 8:3328–3339.

Wen JS , Zhao WZ , Liu JW , et al. Genomic analysis of a Chinese isolate of Getah-like virus and its phylogenetic relationship with other Alphaviruses. Virus Genes, 2007; 35:597–603.

Zhai YG , Wang HY , Sun XH , et al. Complete sequence characterization of isolates of Getah virus (genus Alphavirus, family Togaviridae) from China. J Gen Virol, 2008; 89:1446–1456.

Lin Y , Zhang H , Liang J , et al. Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers. Proc Natl Acad Sci U S A, 2014; 111:E4504–4512.

Cai J , Zhu W , Lin Y , et al. Systematic characterization of the biodistribution of the oncolytic virus M1. Hum Gene Ther, 2020; 31:1203–1213.

Hu C , Liu Y , Lin Y , et al. Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer. Cell Death Dis, 2018; 9:274.

Zhang H , Lin Y , Li K , et al. Naturally existing oncolytic virus M1 is nonpathogenic for the nonhuman primates after multiple rounds of repeated intravenous injections. Hum Gene Ther, 2016; 27:700–711.

Li K , Hu C , Xing F , et al. Deficiency of the IRE1alpha-autophagy axis enhances the antitumor effects of the oncolytic virus M1. J Virol, 2018; 92:e01331-17.

Russell SJ , Peng KW , Bell JC . Oncolytic virotherapy. Nat Biotechnol, 2012; 30:658–670.

Cai J , Lin Y , Zhang H , et al. Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics. Proc Natl Acad Sci U S A, 2017; 114:6812–6817.

Liu Y , Cai J , Liu W , et al. Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade. Cell Death Dis, 2020; 11:1062.

Liang J , Guo L , Li K , et al. Inhibition of the mevalonate pathway enhances cancer cell oncolysis mediated by M1 virus. Nat Commun, 2018; 9:1524.

Cai J , Lin K , Cai W , et al. Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1. Mol Oncol, 2020; 14:3153–3168.

Tan Y , Lin Y , Li K , et al. Selective antagonism of Bcl-xL potentiates M1 oncolysis by enhancing mitochondrial apoptosis. Hum Gene Ther, 2018; 29:950–961.

Zhang H , Li K , Lin Y , et al. Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. Sci Transl Med, 2017; 9:eaam7996.

Xiao X , Liang J , Huang C , et al. DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage. Nat Commun, 2018; 9:4342.

Li K , Liang J , Lin Y , et al. A classical PKA inhibitor increases the oncolytic effect of M1 virus via activation of exchange protein directly activated by cAMP 1. Oncotarget, 2016; 7:48443–48455.

Li K , Zhang H , Qiu J , et al. Activation of cyclic adenosine monophosphate pathway increases the sensitivity of cancer cells to the oncolytic virus M1. Mol Ther, 2016; 24:156–165.

Kim DS , Dastidar H , Zhang C , et al. Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms. Nat Commun, 2017; 8:344.